Literature DB >> 26550250

Relationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysis.

Dilare Adi1, Xiang Xie1, Fen Liu2, Yi-Tong Ma1, Mayila Abudoukelimu1, Yun Wu3, Yong An4, Yi-Ning Yang1, Xiao-Mei Li1, Zhen-Yan Fu1, Yong-Tao Wang1, Bang-Dang Chen2.   

Abstract

OBJECTIVE: Proprotein convertase subtilisin-like kexin type 9 (PCSK9) gene E670G Polymorphism has been reported to be associated with coronary artery disease (CAD) and risk factors. However, the results remain controversial. We sought to perform a meta-analysis to investigate the relationships between genetic polymorphisms of E670G in PCSK9 gene and the risk of CAD.
METHODS: Literature searches were performed to identify all published relevant case-control studies without any language restrictions. Meta-analysis was conducted using the Review Manager software (version 5.2). Heterogeneity was investigated and measured using Cochran's Q-statistic and the inconsistency index (I(2)) test; Crude odds ratios (OR) with their corresponding 95% confidence interval (CI) were calculated.
RESULTS: A total of 5 case-control studies among 871 patients with CAD and 1144 control subjects were included in the meta-analysis. we found a correlation between PCSK9 genetic polymorphisms and increased risk for CAD under all of the genetic model (allele model: OR: 1.56, 95% CI: 1.21-2.01, P < 0.001; dominant model: OR: 1.46, 95% CI: 1.14-1.88, P = 0.003; recessive model: OR: 3.46, 95% CI: 1.19-10.10, P = 0.02; homozygous model: OR: 3.89, 95% CI: 1.35-11.20, P = 0.01; Heterozygous model: OR: 1.43, 95% CI: 1.08-1.92, P = 0.01; respectively).
CONCLUSION: The results of the meta-analysis indicated that genetic polymorphism of E670G in PCSK9 gene might be involved in pathogenesis of CAD; the 670G carriers may be closely related to the risk of CAD.

Entities:  

Keywords:  PCSK9; coronary artery disease; meta-analysis; polymorphisms

Year:  2015        PMID: 26550250      PMCID: PMC4612935     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  23 in total

Review 1.  Precursor convertases in the secretory pathway, cytosol and extracellular milieu.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Essays Biochem       Date:  2002       Impact factor: 8.000

2.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Authors:  Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-01-20       Impact factor: 11.025

3.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

4.  Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.

Authors:  Knut Erik Berge; Leiv Ose; Trond P Leren
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-01-19       Impact factor: 8.311

5.  Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population.

Authors:  Ilaria Guella; Rosanna Asselta; Diego Ardissino; Pier Angelica Merlini; Flora Peyvandi; Sekar Kathiresan; Pier Mannuccio Mannucci; Marco Tubaro; Stefano Duga
Journal:  J Lipid Res       Date:  2010-08-10       Impact factor: 5.922

6.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

7.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

8.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

9.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

10.  Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.

Authors:  Afef Slimani; Yahia Harira; Imen Trabelsi; Walid Jomaa; Faouzi Maatouk; Khaldoun Ben Hamda; Mohamed Naceur Slimane
Journal:  J Mol Neurosci       Date:  2014-03-06       Impact factor: 3.444

View more
  7 in total

Review 1.  Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.

Authors:  Ricardo Stein; Filipe Ferrari; Fernando Scolari
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 2.  Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Anwar Santoso; Yulianto Yulianto; Hendra Simarmata; Abhirama Nofandra Putra; Erlin Listiyaningsih
Journal:  Int J Angiol       Date:  2021-02-18

3.  What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis.

Authors:  Chengfeng Qiu; Pingyu Zeng; Xiaohui Li; Zhen Zhang; Bingjie Pan; Zhou Y F Peng; Yapei Li; Yeshuo Ma; Yiping Leng; Ruifang Chen
Journal:  Lipids Health Dis       Date:  2017-06-12       Impact factor: 3.876

4.  Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease.

Authors:  Shih-Min Chiang; Yi-Sun Yang; Shun-Fa Yang; Chin-Feng Tsai; Kwo-Chnag Ueng
Journal:  J Int Med Res       Date:  2019-04-05       Impact factor: 1.671

5.  Identification of Proteins Interacting with PCSK9 Using a Protoarray Human Protein Microarray.

Authors:  Catherine J Wooten; Sreevidhya T Krishnaji; Quantil M Melendez; Dayami Lopez
Journal:  Int J Biomed Investig       Date:  2019-09-18

6.  Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors.

Authors:  Min-Tao Gai; Dilare Adi; Xiao-Cui Chen; Fen Liu; Xiang Xie; Yi-Ning Yang; Xiao-Ming Gao; Xiang Ma; Zhen-Yan Fu; Yi-Tong Ma; Bang-Dang Chen
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

7.  Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population.

Authors:  Gaojun Cai; Lei Yu; Zhiying Huang; Li Li; Xingli Fu
Journal:  Lipids Health Dis       Date:  2018-09-11       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.